{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:16:46Z","timestamp":1791670606058,"version":"4.3.4"},"reference-count":35,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Nephrology"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>This study aimed to examine associations between cognitive impairment and quality of life and healthcare utilization in patients with chronic kidney disease (CKD) stages 3 to 5.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cross\u2010sectional study was conducted in 379 outpatients with a mean age of 65.7\u2009years at tertiary care hospitals in Thailand. Cognitive function was measured using the Mini\u2010Mental State Examination, and quality of life was measured using the five\u2010dimension European quality of life (EQ\u20105D\u20105L) multi\u2010attribute utility instrument. The effects of cognitive impairment on the likelihood of reporting \u2018no problems\u2019 for each EQ\u20105D dimension, the quality of life scores and healthcare utilization were determined using an appropriate multivariate analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The prevalence of cognitive impairment in patients with CKD stages 3 to 5 was 15.8% (95% confidence interval [CI], 12.3, 19.9). Patients with cognitive impairment had a significantly lower likelihood of achieving good outcomes in the mobility, self\u2010care, usual activities and anxiety\/depression dimensions of the EQ\u20105D\u20105L than those with normal cognition. Patients with cognitive impairment had a significantly lower quality of life score than those with normal cognition by 0.06 points (95% CI, 0.01, 0.10). Cognitive impairment increased the number of emergency visits (rate ratio, RR, 3.47; 95% CI, 1.45, 8.29). Compared to CKD stage 3, CKD stage 5 decreased the quality of life score by 0.06 points (95% CI, 0.01, 0.10) and increased the rate of hospitalization (RR, 2.29; 95% CI, 1.27, 4.12).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Cognitive impairment in patients with CKD was associated with lower quality of life scores and increased healthcare utilization.<\/jats:p><\/jats:sec>","DOI":"10.1111\/nep.13705","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T08:49:00Z","timestamp":1583398140000},"page":"625-633","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cognitive impairment, quality of life and healthcare utilization in patients with chronic kidney disease stages 3 to 5"],"prefix":"10.1111","volume":"25","author":[{"given":"Onnita","family":"Thancharoen","sequence":"first","affiliation":[{"name":"Provincial Public Health Office Kalasin Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3692-6302","authenticated-orcid":false,"given":"Onanong","family":"Waleekhachonloet","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy Mahasarakham University Mahasarakham Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chulaporn","family":"Limwattananon","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences Khon Kaen University Khon Kaen Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirirat","family":"Anutrakulchai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine Khon Kaen University Khon Kaen Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60687-X"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002343"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005101085"},{"key":"e_1_2_8_6_1","unstructured":"Department of Disease Control Ministry of Public Health Thailand. Chronic kidney disease in Thailand. 2018.http:\/\/thaincd.com\/document\/file\/info\/non-communicable-disease. (Thai). Accessed October 3 2019."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000338135"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0745-9"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13173"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.366"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-6686.2008.00028.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.11.026"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000225182.15532.40"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2004.52508.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.07.009"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond MF","year":"2005"},{"key":"e_1_2_8_17_1","volume-title":"Guidelines for the economic evaluation of health technologies: Canada","author":"Canadian Agency for Drugs and Technologies in Health","year":"2006"},{"key":"e_1_2_8_18_1","volume-title":"Guide to the Methods of Technology Appraisal","author":"National Institute for Health and Clinical Excellence","year":"2008"},{"key":"e_1_2_8_19_1","volume-title":"Guidelines for Health Technology Assessment in Thailand","author":"Chaikledkaew U","year":"2013"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001307"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-010-0304-1"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165675"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.73"},{"key":"e_1_2_8_24_1","volume-title":"The MMSE Thai 2002","author":"MMSE\u2010Thai Committee","year":"2005"},{"key":"e_1_2_8_25_1","unstructured":"PattanaphesajJ.Health\u2010Related Quality of Life Measure (EQ\u20105D\u20105L): Measurement Property Testing and its Preference\u2010Based Score in Thai Population [Doctoral Dissertation]: Mahidol University;2014."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21983-w"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15122888"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16030305"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8020214"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15061174"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16203869"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16193623"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S162892"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16214228"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-018-0951-8"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2015.10.010"}],"container-title":["Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnep.13705","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nep.13705","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/nep.13705","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nep.13705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T16:51:08Z","timestamp":1722531068000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/nep.13705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1111\/nep.13705"],"URL":"https:\/\/doi.org\/10.1111\/nep.13705","archive":["Portico"],"relation":{},"ISSN":["1320-5358","1440-1797"],"issn-type":[{"value":"1320-5358","type":"print"},{"value":"1440-1797","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,16]]},"assertion":[{"value":"2020-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}